Keros Therapeutics Inc
$ 11.67
-0.43%
17 Apr - close price
- Market Cap 355,539,000 USD
- Current Price $ 11.67
- High / Low $ 12.00 / 11.56
- Stock P/E 5.07
- Book Value 15.51
- EPS 2.30
- Next Earning Report 2026-05-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.20 %
- 52 Week High 22.55
- 52 Week Low 10.41
About
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with a great unmet medical need. The company is headquartered in Lexington, Massachusetts.
Analyst Target Price
$22.57
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-04 | 2024-08-06 | 2024-05-08 | 2024-02-28 | 2023-11-06 | 2023-08-07 | 2023-05-04 |
| Reported EPS | -0.86 | -0.18 | -0.76 | 3.62 | -1.14 | -1.41 | -1.25 | -1.21 | -1.34 | -1.33 | -1.27 | -1.26 |
| Estimated EPS | -0.6963 | -1.05 | -1.13 | 0.0075 | -0.427 | -1.28 | -1.23 | -1.35 | -1.37 | -1.35 | -1.34 | -1.12 |
| Surprise | -0.1637 | 0.87 | 0.37 | 3.6125 | -0.713 | -0.13 | -0.02 | 0.14 | 0.03 | 0.02 | 0.07 | -0.14 |
| Surprise Percentage | -23.51% | 82.8571% | 32.7434% | 48166.6667% | -166.9789% | -10.1563% | -1.626% | 10.3704% | 2.1898% | 1.4815% | 5.2239% | -12.5% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-05 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.02 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KROS
2026-04-18 19:09:38
Keros Therapeutics director Jean Jacques Bienaime recently purchased 1,000 shares of the company's common stock for $11,700. This transaction was executed under a pre-arranged trading plan, and comes as the stock is down 43% year-to-date, though InvestingPro analysis suggests it may be undervalued. Keros Therapeutics also recently appointed Charles Newton to its Board of Directors to strengthen its leadership with financial expertise.
2026-04-18 07:40:16
Director Jean Jacques Bienaime of Keros Therapeutics (KROS) recently purchased 1,000 shares worth $11,700 at prices between $11.56 and $11.80. This transaction was part of a pre-arranged trading plan, and the stock is considered undervalued by analysts, with price targets up to $30 despite a 43% year-to-date decline. Keros Therapeutics also appointed Charles Newton to its Board of Directors, aiming to strengthen its leadership with financial expertise.
2026-04-18 01:09:02
Jean Bienaime, a Director at Keros Therapeutics Inc (KROS), recently purchased 1,000 shares, increasing his total holdings to 8,450 shares. This transaction is part of a trend where Bienaime has acquired 3,000 shares over the past year without any sales. The company's stock was trading at $11.70 per share, with a market cap of $230.097 million and a P/E ratio significantly lower than the industry median.
2026-04-17 22:09:02
Keros Therapeutics (NASDAQ:KROS) Director Jean Jacques Bienaime recently purchased 1,000 shares of the company's stock for $11,700.00, increasing his total holdings to 8,450 shares. This transaction, executed under a Rule 10b5-1 plan, occurred as the company reported a significant miss on quarterly earnings and revenue expectations. Analysts currently have a consensus "Hold" rating on Keros Therapeutics with a price target of $21.33.
2026-04-17 22:09:02
Bienaime, a director at Keros Therapeutics (NASDAQ:KROS), purchased 1,000 shares of the company's common stock for $11,700 on April 15, 2026. This transaction occurred via a pre-arranged Rule 10b5-1 trading plan, increasing his direct holdings to 8,450 shares. The purchase comes as Keros Therapeutics' stock is down 43% year-to-date, though analysis suggests it may be undervalued, and the company recently appointed Charles Newton to its Board of Directors.
2026-04-17 20:09:02
Keros Therapeutics director Jean Jacques Bienaimé purchased 1,000 shares of the company's common stock at a weighted average price of $11.70 per share on April 15, 2026. This open-market purchase, made under a Rule 10b5-1 trading plan, increased his direct holdings to 8,450 shares. The trade was executed through multiple transactions with prices ranging from $11.56 to $11.80.
